N-Acetyl-N-(4-chloro-2-nitrophenyl)acetamide

We are N-Acetyl-N-(4-chloro-2-nitrophenyl)acetamide CAS:156499-65-9 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests

CAS No: 156499-65-9
Product Name: N-Acetyl-N-(4-chloro-2-nitrophenyl)acetamide
Other Name:
N-Acetyl-N-(4-chloro-2-nitrophenyl)acetamide
n-4-chloro-2-nitrophenyl acetoacetamide
 
Density: 1.438
Molecular Formula: C8H7ClN2O3
Molecular Weight: 214.60600
Exact Mass: 214.01500
PSA: 74.92000
LogP: 2.80280
Index of Refraction: 1.603
 
Specification
Appearance: Light yellow crystal
Assay: ≥99.0%
Loss on drying: ≤0.5%
 
Application
Intermediates of Quizalofop-Ethyl CAS: 76578-14-8.
Be used as pesticide intermediate, mainly used to synthesize herbicide Quizalofop-Ethyl.
 
Package: 25kg/drum, can also be designed according to customer requirements.
Storage: Store in cool place. Keep container tightly closed in a dry and well-ventilated place.

N-Acetyl-N-(4-chloro-2-nitrophenyl)acetamide


Related News: Catalent’s clinical supply network includes nine cGMP-certified clinical packaging facilities across North America, Europe and Asia, and more than 50 strategically-located depots around the world, providing local and regional options for clinical storage, distribution, expiry update and relabeling services, and clinical returns management.2,3-Diethyl-5-methylpyrazine In 2016, the export volume of China’s specialty drug substances reached US $ 3.53 billion, accounting for 13.8% of the total drug substances.Trichloroacetaldehyde Exceeding impurities in the drug substance may cause the product and its preparation to be recalled. The company receives an FDA warning letter or a CEP certificate suspension, which in turn will cause customer compensation, product recall costs, and asset impairment losses to affect the company’s performance.2973-80-0 API (Active Pharmaceutical Ingredient) means the active ingredient which is contained in medicine.The clinical trial International Study of Phase 3 IV RigosErtib, or INSPIRE, was finalized following guidance received from the U.S. Food and Drug Administration and European Medicines Agency.

Related Products
Product Name
(2S,5S)-1-((S)-2-METHOXYCARBONYLAMINO)-3-METHYLBUTYRYL)-5-METHYLPYRROLIDINE-2-CARBOXYLIC ACIDpyrrolidine-2-carboxylic acid View Details
1-[3,5-bis(trifluoromethyl)phenyl]ethanone View Details
1-bromo-3,5-diphenylbenzene View Details
3,4-Difluoronitrobenzene manufacturer 3-[2-(4-chlorophenoxy)phenyl]-1-methylpyrrolidine-2,4-dione manufacturer 2-[[(2S)-4-methyl-2-[(2-methylpropan-2-yl)oxycarbonylamino]pentanoyl]amino]acetic acid manufacturer 5-(2-chloroethyl)-2,3-dihydro-1-benzofuran manufacturer (1S,3S,5S)-tert-Butyl 3-carbamoyl-2-azabicyclo[3.1.0]hexane-2-carboxylate manufacturer